2025-522393-37-00招募中3 期
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Amgen Inc.
- 入组人数
- 11
- 试验地点
- 8
- 主要终点
- Treatment-emergent adverse events, treatment-emergent serious adverse events, and treatment-emergent adverse events of interest during the first 26 weeks of randomized controlled treatment period
研究概览
简要总结
To evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH).
研究设计
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double (Carer, Analyst, Monitor, Investigator, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent as described in Section 11.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Age >18 years or legal adult age within the country, whichever is older and <75 years at the time of signing the informed consent.
- •Participants must have either inadequate response to at least 9 months of SOC or are intolerant to SOC within 6 months of screening. Inadequate response to SOC treatment is defined as ALT ≥ 2 x ULN at screening after at least 9 months of SOC, including prednisone (or equivalent) >5 mg/day and at least one conventional steroid sparing agent at guideline-concordant target or highest appropriate dose, that is AZA or 6-MP at appropriate weight-based dosing (typically up to 2 mg/kg/day AZA or 1 mg/kg/day 6-MP) or MMF up to 2 g/day, as judged appropriate by the investigator and documented in the medical record. . Intolerance to SOC treatment is defined as any clinically significant adverse event related to treatment that results in discontinuation of the medication or prevents dose optimization necessary to achieve or maintain biochemical response, as determined by the PI. Intolerance applies to GCs, AZA, 6-MP, or MMF. Such adverse events are considered clinically significant when they compromise participant’s safety or quality of life, exacerbate comorbid conditions, or render continued use medically inappropriate.
- •Participants with disease activity at screening as follows: ALT ≥ 2 x ULN to ≤ 7 x ULN. ALT ULN values will be gender specific.
- •Participant must have a biopsy proven definitive diagnosis of AIH according to simplified diagnostic criteria (score ≥7). Liver biopsy should be obtained within 90 days prior to randomization. Participants must have a mHAI score ≥ 5 in the biopsy.
- •Participant should be on: • No increase in GC dose during the 28 days immediately preceding whichever biopsy is designated as the baseline sample–historical or screening–and the dose post biopsy must remain unchanged through the day of randomization AND • Stable maximum tolerated doses of AZA or 6-MP for at least 12 weeks prior to screening (baseline) liver biopsy until randomization and during the entire treatment period unless dose reduction is deemed necessary for safety or tolerance reasons OR • Stable maximum tolerated doses of MMF/MPA for at least 12 weeks prior to screening (baseline) liver biopsy until randomization and during the entire treatment period unless dose reduction is deemed necessary for safety or tolerance reasons.
- •Sex and Contraceptive/Barrier Requirements : Participants must use protocol-specified contraception (as defined in Section 5.4.2.1 and Section 5.4.2.2), during treatment and for an additional 6 months after the last dose of trial intervention.
排除标准
- •Diagnosis of definitive overlap autoimmune liver or rheumatologic syndrome with autoimmune hepatitis (eg, AIH+PBC, AIH+PSC, AIH related to Systemic Lupus Erythematosus, etc) where established overlap criteria are met.
- •Blood tests at screening that meet any of the following criteria: • Hemoglobin < 7.5 g/dL • Neutrophils < 1200/mm3 • Platelets < 150 x 109/L • INR > 1.3 • CD19+ B cells at screen <40 cells/µL:an exlusionary value may be repeated. • Serum albumin level < 35 g/L • Direct BIL in serum >ULN • Total BIL ≥ 2.0 mg/dL • ALP > 1.5 x ULN • AST > 7 x ULN Participants with baseline cytopenia (where permitted) may be enrolled if, in the Investigator’s judgment, the cytopenia derives from an alternative to AIH condition (eg, medication effect, nutritional deficiency, anemia of chronic disease etc).
- •Active, clinically significant infection at the time of randomization (investigational product administration may be delayed until recovery, if within screening window, otherwise participant may be rescreened).
- •Known positive test for HIV infection. Evidence of HIV infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
- •Acute liver failure (ALF) at screening (e.g., acute hepatic dysfunction with coagulopathy and any degree of encephalopathy) in the investigator’s judgment.
- •Allergy or reaction to any component of inebilizumab formulation or history of anaphylaxis to any human gamma globulin therapy.
- •Allergy to or intolerance of protocol-required treatment, including medications for prophylaxis of infusion reactions (antipyretic such as paracetamol/acetaminophen or equivalent, diphenhydramine or equivalent, and methylprednisolone or equivalent).
- •Active malignancy or history of malignancy that was active within the last 10 years, except as follows: • In situ carcinoma of the cervix treated with apparent success with curative therapy for > 12 months prior to screening • Curatively treated breast ductal carcinoma in situ • Cutaneous basal cell or squamous cell carcinoma treated with apparent success with curative therapy for > 12 months prior to screening • Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent >3 years prior to screening and without known recurrence or current treatment • Thyroid cancer for which complete surgical resection has been performed within 5 years with well-differentiated histology (papillary thyroid carcinoma or follicular thyroid carcinoma) and there is no evidence of active disease.
- •Receipt of TNF inhibitors (eg, infliximab, adalimumab) within 6 months prior screening.
- •Receipt of immunosuppressive agents such as calcineurin inhibitors (tacrolimus, cyclosporin except eye drops), methotrexate, mammalian target of rapamycin inhibitors (eg, everolimus) within 6 weeks prior screening
- •Receipt of any investigational agent < 12 weeks or < 5 half-lives of the drug (whichever is longer) prior to screening
- •Known immunodeficiency disorder.
- •History of inability to be tapered off of GC therapy due to adrenal insufficiency or due to recurrent or prolonged systemic glucocorticoid therapy for any medical condition other than AIH (eg, severe steroid-dependent asthma) according to PI.
- •All vaccines are prohibited within 4 weeks before the first dose of trial treatment. • Participants are recommended to be administered vaccines at least 4 weeks prior to dosing in accordance with local recommendations prior to enrollment to allow for adequate immune response. (see Section 6.10.1 for vaccine restrictions on trial).
- •Required regular use of medications with known hepatotoxicity (refer Livertox [http://livertox.nih.gov/)]).
- •Presence or history of viral hepatitis infection: • Positive test for, or prior treatment for, hepatitis B. A positive test for hepatitis B is detection of either: Positive for HBsAg OR anti-HBc • Participants with a history of or current HCV infection, even those considered to be cured.
- •Current use of: • GCs (prednisone >20 mg/day, or equivalent dose of other GCs) • AZA >2 mg/kg/day • 6-MP > 1 mg/kg/day • MMF >2 g/day or MPA >1440 mg/day
- •Any concomitant immunosuppressive treatment, alone or in combination with GCs, except for AZA, 6-MP, MMF, and MPA.
- •Undetectable levels of 6-TGN or MPA during screening unless participants are not on AZA or MMF/MPA due to intolerance per protocol.
- •No new Herbal and Dietary Supplements (HDS) products for 4 weeks prior to first dose of inebilizumab.
- •Prior/Concurrent Clinical Trial Experience : Currently receiving a trial intervention, or less than 30 days or 5 half-lives if known (whichever is later) since ending a trial intervention in another investigational device or drug trial.
- •Other Exclusions: Unable to safely undergo a liver biopsy.
- •Participants with concurrent metabolic dysfunction-associated steatohepatitis (MASH) on the screening/baseline liver biopsy, defined on central pathology review by the FLIP/SAF algorithm (steatosis, lobular inflammation, and hepatocellular ballooning all ≥1).
- •Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator.
- •History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety.
- •Currently pregnant (confirmed with positive pregnancy test) or breastfeeding or planning to become pregnant, donate eggs, or breastfeed while on trial until an additional 6 months after the last dose of inebilizumab (if applicable) with highest teratogenic risk.
- •Participants of childbearing potential with a positive pregnancy test assessed by serum pregnancy test at screening and a urine pregnancy test at day 1 visit.
- •Active TB or latent TB with no documented history of adequate treatment per local SOC.
- •Participant unwilling to abstain from donating blood or plasma during the trial.
- •Positive test for TB during screening is defined as positive QuantiFERON® test. At screening, all participants must be tested with an interferon-γ release assay (IGRA) (QuantiFERON®). Positive test for TB during screening is defined as positive QuantiFERON® test
- •History or evidence of uncontrolled alcohol use disorder (AUD), defined as participants who have a history of significant alcohol consumption, ie, consumption of >2 units/day for males and >1 unit/day for females, sustained for ≥ 3 consecutive months.
- •History of recurrent significant infections (eg, requiring hospitalization or IV antibiotics) within the past 12 months.
- •Major surgery within 8 weeks before screening.
- •History of >1 episode of herpes zoster (any grade) and/or any other definite or probable opportunistic infection in the 12 months prior to screening.
- •Severe cardiovascular, respiratory, endocrine, gastrointestinal, hematological, neurological, psychiatric, or systemic disorder, or any other condition that, in the opinion of the Investigator, would place the participant at unacceptable risk of complications, interfere with evaluation of the Investigational product or confound the interpretation of participant safety or study results
- •OLP : In order for participants to continue to OLP, they must: Have completed the randomized controlled treatment period CCI visit and received all doses or not discontinued investigational product for any of the following reasons: • Anaphylaxis or a serious hypersensitivity reaction that occurred within 7 days after IV dosing and cannot be attributed to another known allergen exposure.
- •Any adverse events or significant laboratory abnormality that, in the opinion of the investigator, Amgen, or DMC, warrants discontinuation of dosing.
- •Any life-threatening (grade 4) infection.
- •Any event of sepsis or febrile neutropenia.
- •Any infection listed as either a definite or probable opportunistic infection
- •Any grade 3 IRR.
- •Any grade 4 serious adverse events.
- •Pregnancy or a decision to become pregnant.
- •Malignancy.
- •Participants with decompensated cirrhosis, either historical or present at screening defined by: • Histologic cirrhosis on screening or prior liver biopsy (fibrosis stage F4 / Ishak 5–6), and • Prior hepatic decompensation or Child-Pugh B–C. • Child-Pugh category A at screening, without a history of prior hepatic decompensation (ascites, encephalopathy, variceal bleeding, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), acute-on-chronic liver failure, or progression to decompensated cirrhosis), is eligible.
- •Absolute neutrophil count 800 cells/µL confirmed by repeat testing.
- •Determination that the participant was ineligible for study participation and continuation of investigational product could pose a safety risk to the participant in the judgment of the investigator or the sponsor.
- •Significant noncompliance with the study protocol, as judged by the investigator or Amgen.
- •Receive dose 1 in the OLP within the window of 7 days after the randomized controlled treatment period CCI visit and only after the CCI biopsy has been completed.
- •Participants who meet protocol-defined early escape criteria and discontinue the RCP may enter the OLP, provided they have not discontinued investigational product for safety-related reasons that preclude further dosing.
- 另有 4 项未显示
结局指标
主要结局
Treatment-emergent adverse events, treatment-emergent serious adverse events, and treatment-emergent adverse events of interest during the first 26 weeks of randomized controlled treatment period
Treatment-emergent adverse events, treatment-emergent serious adverse events, and treatment-emergent adverse events of interest during the first 26 weeks of randomized controlled treatment period
Part 2: Achieving modified histologic activity index (mHAI) ≤ 3 at CCI and stable prednisone dose (or equivalent) ≤5 mg/day by CCI
Part 2: Achieving modified histologic activity index (mHAI) ≤ 3 at CCI and stable prednisone dose (or equivalent) ≤5 mg/day by CCI
次要结局
- Achieving normal ALT at week 26
- Change from baseline in ALT at week 26
- Serum concentration of inebilizumab and noncompartmental PK parameters (eg, maximum serum concentration [Cmax] and area under the serum concentration-time curve [AUC])
- Changes from baseline in peripheral B cell counts, including total B cells and B cell subsets during the 26 weeks of randomized controlled treatment period
- Part 2: Achieving sustained normal ALT defined as achieving normal ALT in the 3 consecutive visits CCI including and stable prednisone dose (or equivalent) ≤ 5 mg/day by CCI
- Achieving normal ALT at CCI mHAI ≤ 3 at CCI and stable prednisone dose (or equivalent) ≤ 5
- Achieving stable prednisone dose (or equivalent) ≤ 5 mg/day by CCI
- Achieving flare-free stable GC-free (0 mg) normalization of ALT by CCI
- Cumulative GC dose per participant for AIH during RCP CCI
- Antidrug Antibodies (ADA) directed against inebilizumab during the 78-Week randomized controlled treatment period
- Serum concentration of inebilizumab and noncompartmental PK parameters (eg, Cmax and AUC)
- Treatment-emergent adverse events, treatment-emergent serious adverse events, and treatment-emergent adverse events of interest
- Change from baseline of GC toxicity index score at CCI
- •Achieving normal ALT and stable GC free 0 mg •Time to persistently normal ALT defined as the first occurrence of normal ALT in at least 2 consecutive visits and achieving on stable prednisone or equivalent ≤ 5 mg/day through CCI Change in baseline in ALT, IgG, AST, and mHAI •Achieving normal ALT and IgG •Achieving mHAI ≤3
研究者
Medical Information
Scientific
Amgen Inc.
研究点 (8)
Loading locations...
相似试验
尚未招募
3 期
A Trial of Inebilizumab in Participants With Autoimmune HepatitisAIHAutoimmune HepatitisNCT07598825Amgen180
进行中（未招募）
3 期
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease.2023-508290-81-00Horizon Therapeutics Ireland Designated Activity Company90
招募中
1 期
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune DiseasesNCT07413341Therorna12
招募中
2/3 期
Effectiveness of plasma exchange (biological procedure) in autoimmune liver Disease.CTRI/2025/02/081013Institute of Liver and Biliary Sciences50
招募中
2 期
AHB-171 在慢性乙型肝炎（CHB）参与者中的 II 期临床研究慢性乙型肝炎CTR20261972杭州浩博医药有限公司